开发与上市厂商:美国IDEC公司研制,2003年3月在美国首次上市。 分类名称 严重不良反应包括: 严重输液反应(低血压、血管性水肿、缺氧、支气管痉挛、呼吸窘迫综合征、室颤、心梗、心源性休克)、血小板减少(61%)、中性粒细胞减少(57%)、严重皮肤黏膜反应。 1.全身反应:虚弱、感染、寒战、发热、腹痛、疼痛、头痛、背痛、咽喉刺激、面部发红。 FULL PRESCRIBING INFORMATION
Non-Hodgkin’s lymphoma Zevalin, as part of the Zevalin therapeutic regimen, is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients with rituximab refractory follicular NHL. The Zevalin therapeutic regimen has been given accelerated approval for the treatment of relapsed or refractory, rituximab-naïve, low-grade and follicular NHL based on studies that have shown durable objective overall response rates, a surogate endpoint for progression-free survival [see Clinical Studies (14.2)]. Studies to determine whether the Zevalin therapeutic regimen confers an effect on progression-free survival are ongoing. 2 DOSAGE AND ADMINISTRATION 2.1 Overview of Dosing Schedule 2.2 Zevalin Therapeutic Regimen Dosage and Administration Day 1:
Day 7, 8 or 9: Verify that expected biodistribution is present [see Dosage and Administration (2.5)].
2.3 Directions for Preparation of the In-111 and Y-90 Zevalin Doses Two separate and distinctly-labeled kits are required for preparation of Indium-111 (In-111) Zevalin and Yttrium-90 (Y-90) Zevalin. Follow the detailed instructions for the preparation of radiolabeled Zevalin [see Dosage and Administration (2.4)]. The procedures are different for the preparation of In-111 Zevalin and of Y-90 Zevalin. Directions for Preparation of Radiolabeled In-111 Zevalin Dose Required materials not supplied in the kit:
Method:
Directions for Preparation of Radiolabeled Y-90 Zevalin Dose Required materials not supplied in the kit:
Method:
2.4 Procedure for Determining Radiochemical Purity (RCP) Use the following procedures for radiolabeling both In-111 Zevalin and Y-90 Zevalin:
2.5 Image Acquisition and Interpretation of Biodistribution Assess the biodistribution of In-111 Zevalin by a visual evaluation of whole body planar view anterior and posterior gamma images obtained at 48 - 72 hours after injection. Images at additional time points may be necessary to resolve ambiguities. Acquire whole body anterior/posterior planar images using a large field-of-view gamma camera and medium energy collimators. Suggested gamma camera settings: 256 x 1024 matrix; dual energy photopeaks set at 172 and 247 keV; 15% symmetric window; scan speed of 10 cm/min for the 48-72 hour scan, and 7-10 cm/min for subsequent scans. Expected Biodistribution
Tumor uptake may be visualized however tumor visualization on the In-111 Zevalin scan is not required for Y-90 Zevalin therapy. Altered Biodistribution The criteria for altered biodistribution are met if any of the following is detected on visual inspection of the required gamma images:
Consider bone marrow involvement by lymphoma, increased marrow activity due to recent hematopoietic growth factor administration, and increased reticuloendothelial uptake in patients with HAMA and HACA, as possible causes of prominent bone marrow uptake. Re-assess biodistribution after correction of underlying factors. 2.6 Radiation Dosimetry Estimations of radiation-absorbed doses for In-111 Zevalin and Y-90 Zevalin were performed using sequential whole body images and the MIRDOSE 3 software program. The estimated radiation absorbed doses to organs and marrow from a course of the Zevalin therapeutic regimen are summarized in Table 1. Absorbed dose estimates for the lower large intestine, upper large intestine, and small intestine have been modified from the standard MIRDOSE 3 output to account for the assumption that activity is within the intestine wall rather than the intestine contents.
3.2 mg ibritumomab tiuxetan per 2 mL, single-use vial. 4 CONTRAINDICATIONS None. 5 WARNINGS AND PRECAUTIONS 5.1 Serious Infusion Reactions See also prescribing information for rituximab. Rituximab, alone or as a component of the Zevalin therapeutic regimen, can cause severe including fatal infusion reactions. These reactions typically occur during the first rituximab infusion with time to onset of 30 to 120 minutes. Signs and symptoms of severe infusion reactions may include urticaria, hypotension, angioedema, hypoxia, bronchospasm, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, and cardiogenic shock. Temporarily slow or interrupt the rituximab infusion for less severe infusion reactions. Immediately stop rituximab, In-111 Zevalin, or Y-90 Zevalin administration for severe infusion reactions [see Boxed Warnings and Dosage and Administration (2.2)]. 5.2 Cytopenias Cytopenias with delayed onset and prolonged duration, some complicated by hemorrhage and severe infection, are the most common severe adverse reactions of the Zevalin therapeutic regimen. When used according to recommended doses, the incidences of severe thrombocytopenia and neutropenia are greater in patients with mild baseline thrombocytopenia (100,000 to 149,000 /mm3) compared to those with normal pretreatment platelet counts. Severe cytopenias persisting more than 12 weeks following administration can occur [see Boxed Warning and Adverse Reactions (6.1)]. Monitor patients for cytopenias and their complications (e.g., febrile neutropenia, hemorrhage) for up to 3 months after use of the Zevalin therapeutic regimen. Avoid using drugs which interfere with platelet function or coagulation following the Zevalin therapeutic regimen. 5.3 Severe Cutaneous and Mucocutaneous Reactions Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous dermatitis, and exfoliative dermatitis, some fatal, were reported in post-marketing experience. The time to onset of these reactions was variable, ranging from a few days to 4 months after administration of the Zevalin therapeutic regimen. Discontinue the Zevalin therapeutic regimen in patients experiencing a severe cutaneous or mucocutaneous reaction [see Boxed Warnings and Adverse Reactions (6.3)]. 5.4 Altered Biodistribution Do not administer Y-90 Zevalin to patients with altered biodistribution of In-111 Zevalin. In a post-marketing registry designed to collect biodistribution images and other information in reported cases of altered biodistribution, there were 12 (1.3%) patients reported to have altered biodistribution among 953 patients registered. For descriptions of expected and altered biodistribution image characteristics [see Dosage and Administration (2.4)]. 5.5 Secondary Leukemia and Myelodysplastic Syndrome Myelodysplastic syndrome (MDS) and/or acute myelogenous leukemia (AML) were reported in 5.2% (11/211) of patients enrolled in clinical studies and 1.5% (8/535) of patients included in the expanded-access trial, with median follow-up of 6.5 and 4.4 years, respectively. Among the 19 reported cases, the median time to the diagnosis of MDS or AML was 1.9 years following treatment with the Zevalin therapeutic regimen; however, the cumulative incidence continues to increase [see Adverse Reactions (6.1)]. 5.6 Embryo-Fetal Toxicity (Pregnancy Category D) Based on its radioactivity, Y-90 Zevalin may cause fetal harm when administered to a pregnant woman. If the Zevalin therapeutic regimen is administered during pregnancy, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1)]. 5.7 Extravasation Monitor patents closely for evidence of extravasation during Zevalin infusion. Immediately terminate the infusion if signs or symptoms of extravasation occur and restart in another limb [see Dosage and Administration (2.2)]. 5.8 Immunization The safety of immunization with live viral vaccines following the Zevalin therapeutic regimen has not been studied. Do not administer live viral vaccines to patients who have recently received Zevalin. The ability to generate an immune response to any vaccine following the Zevalin therapeutic regimen has not been studied. 5.9 Laboratory Monitoring Monitor complete blood counts (CBC) and platelet counts following the Zevalin therapeutic regimen weekly until levels recover or as clinically indicated. 5.10 Radionuclide Precautions During and after radiolabeling Zevalin with In-111 or Y-90, minimize radiation exposure to patients and to medical personnel, consistent with institutional good radiation safety practices and patient management procedures. 5.11 Creutzfeldt-Jakob Disease (CJD) The Zevalin therapeutic regimen contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, Zevalin carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) also is considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for albumin. 6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the label:
The most common adverse reactions of the Zevalin therapeutic regimen are neutropenia, thrombocytopenia, anemia, gastrointestinal symptoms (nausea, vomiting, abdominal pain, and diarrhea), increased cough, dyspnea, dizziness, arthralgia, anorexia, anxiety, and ecchymosis. The most serious adverse reactions of the Zevalin therapeutic regimen are prolonged and severe cytopenias, infections (predominantly bacterial in origin), hemorrhage while thrombocytopenic, severe cutaneous and mucocutaneous reactions, infusion reactions (bronchospasm and angioedema), myeloid malignancies and myelodysplasias. Because the Zevalin therapeutic regimen includes the use of rituximab, see prescribing information for rituximab. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data below reflect exposure to the Zevalin therapeutic regimen in 349 patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma treated with a single course at the recommended dose and schedule. The safety population included patients enrolled on the following clinical trials: a dose escalation Phase 1 trial, a Phase 2 open label trial, a randomized Phase 3 trial, and an open label expanded access trial. Patients on these trials were required to have acceptable hematologic, renal and hepatic function, less than 25% bone marrow involvement by NHL, prior external beam radiation therapy not to exceed 25% of the bone marrow, and no prior history of myeloablative therapy/autologous bone marrow transplantation. Patients were not permitted to receive hematopoietic growth factors beginning 2 weeks prior to administration of the Zevalin therapeutic regimen. Table 2 lists adverse reactions that occurred in ≥ 5% of patients. A more detailed description of hematologic toxicities is provided in Table 3.
The following adverse reactions (except for those noted in Table 2) occurred in between 1 and 4% of patients: urticaria (4%), anxiety (4%), dyspepsia (4%), sweats (4%), petechiae (3%), epistaxis (3%), allergic reaction (2%), and melena (2%). Severe or life-threatening adverse reactions occurring in 1-5% of patients included pancytopenia (2%), infusion reaction (1%), gastrointestinal hemorrhage (1%), melena (1%), tumor pain (1%), and apnea (1%). The following severe or life-threatening reactions occurred in <1% of patients: angioedema, tachycardia, urticaria, arthritis, lung edema, pulmonary embolus, encephalopathy, hematemesis, subdural hematoma, and vaginal hemorrhage. Hematologic Reactions Hematologic toxicity was the most frequently observed adverse reaction in clinical trials. Patients in clinical studies were not permitted to receive hematopoietic growth factors beginning 2 weeks prior to administration of the Zevalin therapeutic regimen. Table 3 presents the incidence and duration of severe hematologic toxicity for patients with normal baseline platelet count (≥ 150,000/mm3) treated with the Zevalin therapeutic regimen and patients with mild thrombocytopenia (platelet count 100,000 to 149,000/mm3) at baseline who were treated with a modified Zevalin therapeutic regimen that included a lower Y-90 Zevalin dose at 0.3 mCi per kg (11.1 MBq per kg).
Median time to ANC nadir was 62 days, to platelet nadir was 53 days, and to hemoglobin nadir was 68 days. Information on growth factor use and platelet transfusions is based on 211 patients for whom data were collected. Filgrastim was given to 13% of patients and erythropoietin to 8%. Platelet transfusions were given to 22% of patients and red blood cell transfusions to 20%. Infections During the first 3 months after initiating the Zevalin therapeutic regimen, 29% developed infections. Three percent of patients developed serious infections comprising urinary tract infection, febrile neutropenia, sepsis, pneumonia, cellulitis, colitis, diarrhea, osteomyelitis, and upper respiratory tract infection. Life-threatening infections were reported for 2% of patients that included sepsis, empyema, pneumonia, febrile neutropenia, fever, and biliary stent-associated cholangitis. During follow-up from 3 months to 4 years after the start of treatment with Zevalin, 6% of patients developed infections. Two percent of patients had serious infections comprising urinary tract infection, bacterial or viral pneumonia, febrile neutropenia, perihilar infiltrate, pericarditis, and intravenous drug-associated viral hepatitis. One percent of patients had life-threatening infections that included bacterial pneumonia, respiratory disease, and sepsis. Secondary Leukemia and Myelodysplastic Syndrome There were 19 cases of MDS/AML reported among 746 (2.6%) patients included in clinical studies and the expanded access programs, with a median follow-up of 4.4 years. The overall incidence of MDS/AML among the 211 patients included in the clinical studies was 5.2% (11/211), with a median follow-up of 6.5 years and median time to development of MDS/AML of 2.9 years. The cumulative Kaplan-Meier estimated incidence of MDS/secondary leukemia in this patient population was 2.2% at 2 years and 5.9% at 5 years. The incidence of MDS/AML among the 535 patients in the expanded access programs was 1.5% (8/535) with a median follow-up of 4.4 years and median time to development of MDS/AML of 1.5 years. Multiple cytogenetic abnormalities were described, most commonly involving chromosomes 5 and/or 7. The risk of MDS/AML was not associated with the number of prior treatments (0-1 versus 2-10). 6.2 Immunogenicity As with all therapeutic proteins, there is a potential for immunogenicity. The incidence of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparisons of the incidence of HAMA/HACA to the Zevalin therapeutic regimen with the incidence of antibodies to other products may be misleading. HAMA and HACA response data on 446 patients from 8 clinical studies conducted over a 10-year time period are available. Overall, 11/446 (2.5%) had evidence of either HAMA formation (N=8) or HACA formation (N=4). Six of these patients developed HAMA/HACA after treatment with Zevalin and 5 were HAMA/HACA positive at baseline. Of the 6 who were HAMA/HACA positive, only one was positive for both. Furthermore, in 6 of the 11 patients, the HAMA/HACA reverted to negative within 2 weeks to 3 months. No patients had increasing levels of HAMA/HACA at the end of the studies. Only 6/446 patients (1.3%) had developed evidence of antibody formation after treatment with Zevalin, and of these, many either reverted to negative or decreased over time. This data demonstrates that HAMA/HACA develop infrequently, are typically transient, and do not increase with time. 6.3 Post-Marketing Experience The following adverse reactions have been identified during post-approval use of the Zevalin therapeutic regimen in hematologic malignancies. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to the Zevalin therapeutic regimen.
7 DRUG INTERACTIONS No formal drug interaction studies have been performed with Zevalin. Patients receiving medications that interfere with platelet function or coagulation should have more frequent laboratory monitoring for thrombocytopenia. 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Teratogenic Effects: Category D [see Warnings and Precautions (5.6)]: Based on its radioactivity, Y-90 Zevalin may cause fetal harm when administered to a pregnant woman. Immunoglobulins are known to cross the placenta. There are no adequate and well-controlled studies in pregnant women. Animal reproductive toxicology studies of Zevalin have not been conducted. Advise women of childbearing potential to use adequate contraception. Inform women who become pregnant while receiving Zevalin of the potential fetal risks [see Patient Counseling Information (17)]. 8.3 Nursing Mothers Because human IgG is excreted in human milk, it is expected that Zevalin would be present in human milk. Because of the potential for adverse reactions in nursing infants from Y-90 or In-111 Zevalin, a decision should be made to discontinue nursing or not administer the Zevalin therapeutic regimen, taking into account the importance of the drug to the mother. 8.4 Pediatric Use The safety and effectiveness have not been established in pediatric patients. 8.5 Geriatric Use Of 349 patients treated with the Zevalin therapeutic regimen in clinical studies, 38% (132 patients) were age 65 years and over, while 12% (41 patients) were age 75 years and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out. 10 OVERDOSAGE Severe cytopenias which may require stem cell support have occurred at doses higher than the recommended maximum total dose of 32 mCi. 11 DESCRIPTION Zevalin (ibritumomab tiuxetan) is the immunoconjugate resulting from a stable thiourea covalent bond between the monoclonal antibody ibritumomab and the linker-chelator tiuxetan [N-[2-bis(carboxymethyl)amino]-3-(p-isothiocyanatophenyl)-propyl]-[N-[2-bis(carboxymethyl)amino]-2-(methyl)-ethyl]glycine. This linker-chelator provides a high affinity, conformationally restricted chelation site for Indium-111 or Yttrium-90. The approximate molecular weight of ibritumomab tiuxetan is 148 kD. The antibody moiety of Zevalin is ibritumomab, a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen. Ibritumomab tiuxetan is a clear, colorless, sterile, pyrogen-free, preservative-free solution that may contain translucent particles. Each single-use vial includes 3.2 mg of ibritumomab tiuxetan in 2 mL of 0.9% Sodium Chloride. Physical/Radiochemical Characteristics of In-111 Indium-111 decays by electron capture, with a physical half-life of 67.3 hours (2.81 days). The product of radioactive decay is non-radioactive Cadmium-111. Radiation emission data for In-111 are summarized in Table 4.
External Radiation The exposure rate constant for 1 mCi (37 MBq) of In-111 is 8.3 x 10-4 C/kg/hr (3.2 R/hr) at 1 cm. To allow correction for physical decay of In-111, the fractions that remain at selected intervals before and after the time of calibration are shown in Table 5.
Physical/Radiochemical Characteristics of Y-90 Yttrium-90 decays by emission of beta particles, with a physical half-life of 64.1 hours (2.67 days). The product of radioactive decay is non-radioactive Zirconium-90. The range of beta particles in soft tissue (χ90) is 5 mm. Radiation emission data for Y-90 are summarized in Table 6.
External Radiation The exposure rate for 1 mCi (37 MBq) of Y-90 is 8.3 x 10-3 C/kg/hr (32 R/hr) at the mouth of an open Y-90 vial. To allow correction for physical decay of Y-90, the fractions that remain at selected intervals before and after the time of calibration are shown in Table 7.
12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Ibritumomab tiuxetan binds specifically to the CD20 antigen (human The chelate tiuxetan, which tightly binds In-111 or Y-90, is covalently linked to ibritumomab. The beta emission from Y-90 induces cellular damage by the formation of free radicals in the target and neighboring cells. Ibritumomab tiuxetan binding was observed in vitro on lymphoid cells of the bone marrow, lymph node, thymus, red and white pulp of the spleen, and lymphoid follicles of the tonsil, as well as lymphoid nodules of other organs such as the large and small intestines. 12.2 Pharmacodynamics In clinical studies, administration of the Zevalin therapeutic regimen resulted in sustained depletion of circulating B cells. At four weeks, the median number of circulating B cells was zero (range, 0-1084/mm3). B-cell recovery began at approximately 12 weeks following treatment, and the median level of B cells was within the normal range (32 to 341/mm3) by 9 months after treatment. Median serum levels of IgG and IgA remained within the normal range throughout the period of B-cell depletion. Median IgM serum levels dropped below normal (median 49 mg/dL, range 13-3990 mg/dL) after treatment and recovered to normal values by 6-months post therapy. 12.3 Pharmacokinetics Pharmacokinetic and biodistribution studies were performed using In-111 Zevalin (5 mCi [185 MBq] In-111, 1.6 mg ibritumomab tiuxetan). In an early study designed to assess the need for pre-administration of unlabeled antibody, only 18% of known sites of disease were imaged when In-111 Zevalin was administered without unlabeled ibritumomab. When preceded by unlabeled ibritumomab (1.0 mg/kg or 2.5 mg/kg), In-111 Zevalin detected 56% and 92% of known disease sites, respectively. These studies were conducted with a Zevalin therapeutic regimen that included unlabeled ibritumomab. In pharmacokinetic studies of patients receiving the Zevalin therapeutic regimen, the mean effective half-life for Y-90 activity in blood was 30 hours, and the mean area under the fraction of injected activity (FIA) vs. time curve in blood was 39 hours. Over 7 days, a median of 7.2% of the injected activity was excreted in urine. 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity and mutogenicity studies have not been conducted. However, radiation is a potential carcinogen and mutagen. No animal studies have been performed to determine the effects of Zevalin on fertility in males or females. In clinical studies, the Zevalin therapeutic regimen results in a significant radiation dose to the testes: the radiation dose to the ovaries has not been established [see Dosage and Administration (2.6)]. There is a potential risk that the Zevalin therapeutic regimen could cause toxic effects on the male and female gonads. Effective contraceptive methods should be used during treatment and for up to 12 months following the Zevalin therapeutic regimen [see Patient Counseling Information (17)]. 13.2 Animal Toxicology and/or Pharmacology Animal reproductive toxicology studies of the Zevalin regimen have not been conducted. Because the Zevalin therapeutic regimen includes the use of rituximab, also see prescribing information for rituximab. 14 CLINICAL STUDIES The safety and efficacy of the Zevalin therapeutic regimen were evaluated in 2 multi-center trials, enrolling a total of 197 subjects and a third study enrolling a total of 30 subjects. 14.1 Relapsed Follicular Lymphoma Refractory to Rituximab Study 1 was a single arm study of 54 patients with relapsed follicular lymphoma, who were refractory to rituximab treatment. Patients had a World Health Organization (WHO) Performance Status (PS) 0-2, <25% bone marrow involvement by NHL, no prior bone marrow transplantation, and acceptable hematologic, renal, and hepatic function. Refractoriness to rituximab was defined as failure to achieve a complete or partial response or time-to-disease-progression (TTP) of < 6 months. The primary efficacy endpoint of the study was the overall response rate (ORR) using the International Workshop Response Criteria (IWRC). Secondary efficacy endpoints included time to disease progression (TTP) and duration of response (DR). Table 8 summarizes efficacy data from Study 1. 14.2 Relapsed or Refractory, Rituximab-Naïve, Low-Grade or Follicular NHL Study 2 was a randomized (1:1), open-label, multicenter study comparing the Zevalin therapeutic regimen with rituximab. The trial was conducted in 130 patients with relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma (NHL); no patient had received prior rituximab. Patients had histologically confirmed NHL requiring therapy, a WHO PS 0-2, <25% bone marrow involvement by NHL, no prior bone marrow transplantation, and acceptable hematologic function. Sixty-four patients received the Zevalin therapeutic regimen, and 66 patients received rituximab given as an IV infusion at 375 mg per m2 weekly times 4 doses. The primary efficacy endpoint of the study was ORR using the IWRC (see Table 8). The ORR was significantly higher for patients receiving the Zevalin therapeutic regimen (83% vs. 55%, p<0.001). Time-to-disease-progression was not significantly different between study arms.
Study 3 was a single arm study of 30 patients of whom 27 had relapsed or refractory low-grade, follicular NHL and a platelet count 100,000 to 149,000/mm3. Patients with ≥ 25% lymphomatous marrow involvement, prior myeloablative therapy with stem cell support, prior external beam radiation to > 25% of active marrow or neutrophil count <1,500/mm3 were ineligible for Study 3. All patients received [0.3 mCi per kg (11.1 MBq per kg). Objective, durable clinical responses were observed [89% ORR (95% CI: 70-97%) with a median duration of response of 11.6 months (range: 1.0-42.4+ months)] 16 HOW SUPPLIED/STORAGE AND HANDLING There are two kits necessary for preparation of the Zevalin therapeutic regimen: one for preparation of In-111 radiolabeled Zevalin (NDC 68152-0104-04) and one for preparation of Y-90 radiolabeled Zevalin (NDC 68152-0103-03). The contents of all vials are sterile, pyrogen-free, contain no preservatives, and are not radioactive. Each kit contains four identification labels and the following four vials:
Indium-111 Chloride Sterile Solution (In-111 Chloride) must be ordered separately from either GE Healthcare, or Covidien. Yttrium-90 Chloride Sterile Solution is shipped directly from MDS Nordion upon placement of an order for the Y-90 Zevalin kit. Rituximab (Rituxan®, Biogen Idec, Inc. and Genetech USA Inc.) must be ordered separately. Storage Store kits at 2-8°C (36-46°F). Do not freeze. 注:以下产品不同规格和不同价格,购买时请以电话咨询为准! |
替伊莫单抗,泽娃灵(Ibritumomab Tiuxetan/Zevalin)简介:
开发与上市厂商:美国IDEC公司研制,2003年3月在美国首次上市。
分类名称 一级分类:抗肿瘤药物 二级分类:其他 三级分类: 药品英文名 Ibritumomab Tiuxetan 药品别名 替伊莫单抗、泽娃灵、Ze ... 责任编辑:admin |
最新文章更多推荐文章更多热点文章更多 |